Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominick J Angiolillo

Showing results (191-200 of 760) with videos related to

Pageof 76
Sort By:
American Heart Journal|July 31, 2008
Clinical profile of prasugrel, a novel thienopyridineDominick J Angiolillo, Eric R Bates, Theodore A Bass
Expert Opinion on Drug Safety|October 19, 2019
Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigmsSergio Buccheri, Davide Capodanno, Stefan James, et al.
Diabetes & Vascular Disease Research|October 6, 2010
Antithrombotic therapy in patients with diabetes mellitus and coronary artery diseaseJosé Luis Ferreiro, Ángel R Cequier, Dominick J Angiolillo
Advances in Cardiology|August 22, 2012
PrasugrelAntonio Tello-Montoliu, Salvatore D Tomasello, Dominick J Angiolillo
Future Cardiology|September 26, 2015
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial developmentFrancesco Franchi, Fabiana Rollini, Yongwhi Park, et al.
Expert Opinion on Drug Safety|December 19, 2015
A Safety Evaluation of Cangrelor in Patients Undergoing PCIFrancesco Franchi, Fabiana Rollini, Yongwhi Park, et al.
Progress in Cardiovascular Diseases|August 17, 2015
Novel Antiplatelet Agents: The Current State and What Is Coming Down the PikeFrancesco Franchi, Fabiana Rollini, Yongwhi Park, et al.
Circulation|May 23, 2018
Response by Angiolillo et al to Letter Regarding Article, "International Expert Consensus Document on Switching Platelet P2Y<sub>12</sub> Receptor Inhibiting Therapies"Dominick J Angiolillo, Matthew J Price, Robert F Storey
American Heart Journal|July 31, 2008
Current antiplatelet therapies: benefits and limitationsDominick J Angiolillo, Luis A Guzman, Theodore A Bass
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 15, 2026
Prasugrel should be preferred over ticagrelor in acute coronary syndromes: pros and consDominick J Angiolillo, Adnan Kastrati, Marco Frazzetto, et al.
Pageof 76

Showing results (191-200 of 760) with videos related to

Sort By:
Pageof 76
American Heart Journal|July 31, 2008
Clinical profile of prasugrel, a novel thienopyridineDominick J Angiolillo, Eric R Bates, Theodore A Bass
Expert Opinion on Drug Safety|October 19, 2019
Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigmsSergio Buccheri, Davide Capodanno, Stefan James, et al.
Diabetes & Vascular Disease Research|October 6, 2010
Antithrombotic therapy in patients with diabetes mellitus and coronary artery diseaseJosé Luis Ferreiro, Ángel R Cequier, Dominick J Angiolillo
Advances in Cardiology|August 22, 2012
PrasugrelAntonio Tello-Montoliu, Salvatore D Tomasello, Dominick J Angiolillo
Future Cardiology|September 26, 2015
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial developmentFrancesco Franchi, Fabiana Rollini, Yongwhi Park, et al.
Expert Opinion on Drug Safety|December 19, 2015
A Safety Evaluation of Cangrelor in Patients Undergoing PCIFrancesco Franchi, Fabiana Rollini, Yongwhi Park, et al.
Progress in Cardiovascular Diseases|August 17, 2015
Novel Antiplatelet Agents: The Current State and What Is Coming Down the PikeFrancesco Franchi, Fabiana Rollini, Yongwhi Park, et al.
Circulation|May 23, 2018
Response by Angiolillo et al to Letter Regarding Article, "International Expert Consensus Document on Switching Platelet P2Y<sub>12</sub> Receptor Inhibiting Therapies"Dominick J Angiolillo, Matthew J Price, Robert F Storey
American Heart Journal|July 31, 2008
Current antiplatelet therapies: benefits and limitationsDominick J Angiolillo, Luis A Guzman, Theodore A Bass
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 15, 2026
Prasugrel should be preferred over ticagrelor in acute coronary syndromes: pros and consDominick J Angiolillo, Adnan Kastrati, Marco Frazzetto, et al.
Pageof 76